South Korea's Kwangdong Pharmaceutical announced on Tuesday that it signed a stock purchase agreement to acquire Precision Biosensor Inc., a company specializing in in-vitro diagnostic devices.
Precision Bio manufactures and sells diagnostic devices and cartridges for both human and animal use.
Kwangdong Pharmaceutical stated that it plans to acquire a 29.7% stake in Precision Bio from its largest shareholder, i-SENS Inc., and others. The acquisition amount is 17 billion won ($12.2 million).
Kwangdong Pharmaceutical explained that the purpose of this stock acquisition is to build infrastructure for entering the personalized healthcare business.
We use cookies to provide the best user experience. By continuing to browse this website, you will be considered to accept cookies. Please review our Privacy Policy to learn our cookie policy.